Sign in to view content

Brolucizumab for the Treatment of Visual Impairment Due to Diabetic Macular Edema: 52-Week Results From the KESTREL and KITE Studies

David M. Brown, MD

Video
Published 2021

Related

Three-Year Outcomes of the PALADIN Phase IV Study: Comparison of Anatomical Metrics, Efficacy, and Treatment Burden Post FAc
Christopher D. Riemann, MD
Annual Meeting Talks
2022
Durability of Combination Therapy of Sozinibercept, an Anti-VEGF-C/D 'Trap' With Ranibizumab in nAMD or Aflibercept in DME
Nathan C. Steinle, MD
Annual Meeting Talks
2024
Intravitreal Liposome-Encapsulated Bromfenac for the Treatment of Refractory Diabetic Macular Edema
Hugo Quiroz-Mercado, MD
Annual Meeting Talks
2020

Category: Diabetic Retinopathy

See more